| 1. | As      of date, the principal amount of the Annual License Fee due to be paid to      Yeda consist of ***** (the “Accumulated      Annual Fee”). As previously agreed by Yeda and Company, such      Accumulated Annual Fee bears an accumulated interest at the rate of *****      (the “Interest”). The Accumulated      Annual Fee plus accrued Interest was due to be paid to Yeda by the Company      no later than *****. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | Commencing      upon the Effective Date hereof, the Accumulated Annual Fee plus accrued      Interest thereon (the “Due Payment”) shall be      paid to Yeda within ***** of recipe of the proceeds from an Entitling      Event, as such term is defined in the Research and License      Agreement. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Commencing      upon the Effective Date hereof, Section 10.2 of the Research and License      Agreement, as amended from time to time, shall be replaced in its entirety      with the following provisions; |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| 4. | The      Royalty Payment as aforesaid shall be paid in lieu of the Annual Licensee      Fees referred to in Section 10.2 of the Research and License Agreement,      which shall not be payable as of the Effective Date. The Royalty Payment      shall be made by the Company (also on behalf of Sublicensees) for as long      as the License under the Research and License Agreement is in      force. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The      Company undertakes that all sales of Products by the Company and each      Sublicensee shall be for cash consideration  only. |
|----|----------------------------------------------------------------------------------------------------------------------------------------|

| 6. | In      calculating Net Sales all amounts shall be expressed in US Dollars and any      amount received      in a currency other than US Dollars shall be translated into US Dollars,      for the purposes of calculation, in accordance with the applicable      exchange rate between the US Dollar and such currency on the date of such      receipt. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | sales      taxes (including value added taxes) to the extent applicable to such sale      and included in the invoice in respect of such  sale; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | credits      or allowances, if any, actually granted on account of price adjustments,      recalls, rejections or returns of Products previously  sold; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Bad      Debts, meaning invoices which have been recognized by the Company as bad      debts and which amounts the Company’s accountants have agreed to include      as bad debts in the Company’s financial statements in according with      generally accepted accounting principles and in accordance with Israeli      income tax regulations, and which derive from Net Sales in respect of      which royalties were paid by the Company pursuant hereunder provided      that: |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7. | The      Royalty payment shall be paid to Yeda in US Dollars no later than 45      (forty five) days after the end of each calendar quarter, commencing with      the first calendar quarter in which any Net Sales are made by the      Company. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8. | Failure      by the Company to fulfill its obligations under the terms of this      Amendment shall be considered as a material breach of the Research and      License Agreement, and Yeda shall be entitled, notwithstanding clause      14.2.1 to the Research and License Agreement, to immediately terminate the      Research and License Agreement and the License by serving a letter of      termination on the Company. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9. | For      the avoidance of doubt, Biogal Advanced Biotechnology Ltd. hereby      undertakes to serve as guarantor for the full and timely performance by      the Company of all of its obligations hereunder, including without      limitation, the full and prompt payment of the total sum of the Due      Payment and the Royalty Payments. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10. | This      Amendment shall be effective upon execution by all those signatories      thereof, effective      as of the Effective Date. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------|

| 11. | Except      for those provisions, which are amended in accordance with the terms of      this Amendment, the remainder of the terms and conditions of the Research      and License Agreement, as has been amended from time to time, shall      continue in full force and effect and shall, mutatis mutandis, apply to      this Amendment. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12. | In      any event of a conflict between and conditions contained in this Amendment      and the Research and License Agreement, as has been amended from time to      time, the terms contained in this Amendment shall  govern. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13. | This      Amendment may be executed in any number of counterparts, each of which      shall be deemed an original and enforceable against the parties actually      executing such counterpart, and all of which together shall constitute one      and the same instrument. Facsimile signatures shall be binding as original      signatures |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| YEDA      RESEARCH ANDDEVELOPMENT      COMPANY LTD.                   |   | MOR      RESEARCH APPLICATIONSLTD.                                    |
|-----------------------------------------------------------------------|--------|-----------------------------------------------------------------------|
|                                                                  |   |                                                                  |
| By:    __________________________________________ |   | By:    __________________________________________ |
|                                                                  |   |                                                                  |
| Title:   _________________________________________     |   | Title:   _________________________________________     |
|                                                                  |   |                                                                  |
|  BIOGAL      LTD.                                                |   | BIOGAL      ADVANCED BIOTECHNOLOGYLTD.                                |
|                                                                  |   |                                                                  |
| By:    __________________________________________ |   | By:    __________________________________________ |
|                                                                  |   |                                                                  |
| Title:   _________________________________________     |   | Title:   _________________________________________     |

----